Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reaffirmed at HC Wainwright

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $69.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 22.95% from the stock’s previous close. Several other research analysts […]

Leave a Reply

Your email address will not be published.

Previous post Could a ‘Weather Dome’ Bring an End to NASCAR’s Cancelled Race Problem?
Next post New Fortress Energy (NASDAQ:NFE) Given New $17.00 Price Target at Stifel Nicolaus